Gene Therapy Market Size & Share 2026 - 2034

Gene Therapy Market Size

The global gene therapy market size was valued at USD 10.4 billion in 2025. The market is expected to grow from USD 12 billion in 2026 to USD 51.3 billion in 2034, at a CAGR of 19.9% during the forecast period, according to the latest report published by Global Market Insights Inc.

The gene therapy market is witnessing rapid growth, driven by continuous advances in gene delivery technologies, expanding clinical research, rising regulatory approvals, and increasing investment from both public and private organizations. As healthcare shifts toward precision medicine, gene therapy is becoming a preferred approach for treating inherited disorders, rare diseases, and certain cancers by addressing the underlying genetic cause rather than only managing symptoms.

The growing prevalence of conditions such as spinal muscular atrophy (SMA), hemophilia, inherited retinal disorders, and other rare genetic diseases continues to expand the eligible patient population. Globally, hemophilia affects an estimated 836,000 individuals, including approximately 284,000 severe cases, highlighting the significant demand for long-lasting treatment options. Unlike conventional therapies that often require lifelong management, many gene therapy treatments are designed as one-time interventions capable of delivering durable or potentially curative outcomes, making them increasingly attractive to healthcare providers, patients, and payers.

Market expansion is further supported by improvements in viral and non-viral vector technologies, the rapid growth of cell and gene therapy manufacturing services, stronger clinical pipelines, and a rising number of commercial product launches. Gene therapy works by replacing, repairing, inactivating, or introducing genetic material within a patient's cells to restore normal biological function and treat disease at its source.

Leading companies, including Novartis, Spark Therapeutics (Roche), Bluebird Bio, BioMarin, and Pfizer, continue to strengthen the competitive landscape through strategic collaborations, robust R&D investments, manufacturing expansion, and successful commercialization of innovative therapies, accelerating global adoption and reinforcing the long-term growth outlook for the gene therapy market.

Market Dynamics

Drivers

Rising Investments in Research and Development Accelerate Gene Therapy Innovation

Growing investments in gene therapy research and development are significantly accelerating market growth by supporting the discovery of next-generation genetic medicines and expanding clinical pipelines. Increased funding from biotechnology companies, pharmaceutical firms, venture capital investors, and government organizations is driving innovation in viral vectors, gene editing technologies, and cell-based therapies. These investments also improve manufacturing capabilities, enhance clinical trial efficiency, and speed regulatory submissions.

Increasing Product Approvals and Commercial Launches Expand Market Adoption

The growing number of gene therapy product approvals and commercial launches is driving wider market adoption by improving patient access to innovative treatments. Regulatory agencies are approving more gene therapies for rare diseases, inherited disorders, hematological conditions, and selected cancers, reflecting advances in clinical efficacy and safety. Each successful approval strengthens industry confidence, encourages additional investment, and validates emerging therapeutic platforms. Commercial launches are also expanding treatment availability through broader healthcare partnerships, reimbursement initiatives, and improved manufacturing capacity.

Opportunity

Rising Demand for Personalized and Precision Gene Therapies

Personalized and precision gene therapy is creating significant growth opportunities for the gene therapy market as healthcare shifts toward patient-specific treatment approaches. Advances in genomic sequencing, biomarker discovery, and AI-driven diagnostics enable developers to design therapies that target the underlying genetic cause of disease rather than only managing symptoms. This approach is particularly valuable for rare genetic disorders, inherited diseases, oncology, and neurology, where treatment outcomes improve through individualized interventions.

Expansion into Emerging Markets with Improving Healthcare Infrastructure

Emerging economies across Asia-Pacific, Latin America, and the Middle East present substantial opportunities for the global gene therapy market due to improving healthcare infrastructure, rising healthcare expenditure, and expanding access to advanced medicines. Governments are increasing investments in biotechnology research, genomic medicine, and specialized treatment centers while strengthening regulatory frameworks for advanced therapies.

Restraint/Challenge

High Cost of Gene Therapy Treatment Limits Large-Scale Adoption

The high cost of gene therapy remains one of the biggest challenges restricting market growth. Most approved gene therapies involve complex research, personalized manufacturing, specialized cold-chain logistics, and extensive clinical testing, resulting in treatment costs that can reach hundreds of thousands or even millions of dollars per patient. Limited reimbursement coverage, particularly in developing economies, further reduces patient access.

Lack of Standardized Regulatory Frameworks Delays Market Expansion

The absence of harmonized global regulatory standards continues to slow the development and commercialization of gene therapies. Regulatory requirements for clinical trials, manufacturing quality, long-term patient monitoring, and product approvals vary significantly across countries, creating challenges for developers seeking multi-regional launches. In addition, evolving guidelines for viral vectors, genome editing technologies, and personalized therapies increase compliance complexity and development timelines.

Gene Therapy Market Trends

The Gene Therapy Market is witnessing strong momentum as regulatory approvals, expanding clinical pipelines, and advances in precision medicine accelerate commercialization. One of the most significant trends is the growing number of FDA-approved gene therapies and late-stage clinical candidates, reflecting increasing confidence in the safety, efficacy, and long-term potential of gene-based treatments.

As of March 2024, the FDA had approved 36 gene therapies, while more than 500 candidates remained in development, with industry expectations of 10–20 new approvals annually. Regulatory bodies are also expanding the use of fast-track, breakthrough, and priority review pathways to speed patient access to innovative therapies, particularly for rare genetic diseases and other conditions with high unmet medical needs. At the same time, the market is benefiting from the rapid adoption of personalized gene therapy, supported by advances in genomic sequencing, bioinformatics, and gene editing technologies that enable treatments tailored to specific genetic mutations, improving clinical outcomes while reducing adverse effects.

Beyond rare inherited disorders, companies are increasingly developing gene therapies for cancer, cardiovascular diseases, neurological disorders, and other chronic conditions, significantly widening the addressable market and creating new commercial opportunities. Rising investments from biotechnology companies, pharmaceutical firms, venture capital investors, and government organizations continue to strengthen research, manufacturing capabilities, and clinical development.

For example, public and private organizations across the U.S. and Europe invested more than USD 15 billion in cell and gene therapies between 2018 and 2019, accelerating innovation and product development. As the global gene therapy pipeline continues to expand across multiple therapeutic areas, the market is expected to experience sustained growth, supported by technological advancements, favorable regulatory frameworks, and increasing demand for targeted, disease-modifying treatments.

Gene Therapy Market Analysis

Based on the vector, the global market is divided into viral vectors and non-viral vectors. The viral vectors include retroviral vectors, adeno-associated virus vectors, lentiviral vectors, and other viral vectors. The viral vectors segment accounted for 84.8% of the market in 2025.
 

• Viral vectors hold a significant market share in the market since they have proven highly efficient in the delivery of genetic material to target cells.
   
• Viral vectors, such as adeno-associated viruses (AAV) and lentiviruses, are preferred for their ability to produce stable and long-term gene expression, an important prerequisite for therapeutic efficacy.
   
• Additionally, the broad use of viral vectors is supported by established manufacturing processes and a positive track record in approved gene therapies like Zolgensma and Luxturna.
   
• While there is ongoing research on non-viral delivery methods, viral vectors remain the gold standard and continue to drive a large part of the market's innovation and growth due to their reliability and efficacy.
   
• The non-viral vectors segment was valued at USD 1.3 billion in 2024 and is anticipated to grow at a CAGR of 21.7% over the forecast years. The segment includes plasmid DNA, lipid nanoparticles (LNPs), oligonucleotides, and other non-viral vectors.
   
• Non-viral vectors are generally considered safer compared to viral vectors. They do not carry the risk of viral replication or integration into the host genome, which can cause unintended effects. Non-viral vectors are less likely to trigger immune responses and are associated with lower toxicity, making them attractive for clinical use.
   

Based on the delivery method, the gene therapy market is segmented into in vivo gene therapy and ex vivo gene therapy. The in vivo gene therapy segment dominated the market in 2025 with a revenue of USD 6.7 billion.
 

• In vivo gene therapy enables systemic treatment, meaning it can reach multiple sites or organs throughout the body. This is particularly beneficial for diseases that affect multiple areas or have systemic manifestations, allowing for a comprehensive therapeutic approach.
   
• In addition, the development of advanced delivery systems such as viral vectors, nanoparticles, and lipid-based carriers, has improved the efficiency and specificity of in vivo gene therapy.
   
• These advancements enhance the targeted delivery of genetic material and improve the safety and efficacy of the therapy. This is expected to boost segmental growth in the market.
   
• The ex vivo delivery method is anticipated to witness growth at a CAGR of 16.6% over the analysis period, reaching USD 16.8 billion by 2034.
   
• The ex vivo delivery method is experiencing rapid growth within the market due to its ability to provide precise and controlled genetic modification outside the patient’s body before reintroducing the treated cells. This approach minimizes risks associated with direct in vivo delivery, such as immune reactions and off-target effects, making it especially effective for blood disorders and certain cancers.
   
• As a result, ex vivo methods are becoming a preferred strategy in the development of next-generation gene therapies, contributing substantially to overall market expansion.
   

Based on the gene type, the gene therapy market is segmented into antigen-encoding genes, cytokine-encoding genes, tumor suppressor genes, suicide genes, gene replacement (for deficiency), growth factor genes, receptor-encoding genes, and other gene types. The gene replacement (for deficiency) segment dominated the market in 2025 with a revenue of USD 2.2 billion.
 

• Gene replacement for genetic deficiencies has proven effective against various inherited diseases caused by missing or faulty genes. It involves introducing a normal copy of the defective gene to restore normal cell function, which is particularly valuable for monogenic diseases such as spinal muscular atrophy and hemophilia.
   
• The success of several approved gene replacement therapies has enhanced trust among investors and physicians, propelling further research and business in this area.
   
• On the other hand, the antigen-encoding genes segment is anticipated to witness growth at a CAGR of 21.9%.
   
• Antigen-based gene therapies can be employed as immunotherapeutic strategies. By introducing genes encoding specific antigens into a patient’s cells, the immune system can be activated or enhanced to recognize and attack tumor cells or pathogens. This approach has shown promise in cancer gene therapy and cancer immunotherapy, where antigens derived from cancer cells are targeted to elicit an immune response against tumors.
   
• Additionally, antigens can serve as specific targets for gene therapy interventions. By identifying antigens associated with particular diseases or conditions, gene therapies can be designed to specifically target and modulate the expression of these antigens, leading to more precise therapeutic effects. This is expected to support segmental growth in the market.
   

Based on the indications, the gene therapy market is segmented into oncology, neurological disorders, hemophilia A & B, hepatological diseases, inherited retinal disease, peripheral arterial disease, and other indications. The oncology segment dominated the market with a market share of 42.2% in 2025 and is anticipated to grow at a CAGR of 22.2% between 2026 – 2034. The oncology segment is further segmented into Acute Lymphoblastic Leukemia (ALL), large B-cell lymphoma, head & neck squamous cell carcinoma, and melanoma.
 

• Gene therapy allows targeted and precise delivery of therapeutic genes to cancer cells.
   
• By selectively modifying or killing cancer cells while sparing healthy cells, gene therapy minimizes off-target effects and reduces the toxicity associated with traditional treatments.
   
• Moreover, gene therapy has the potential to enhance the efficacy of traditional cancer treatments such as chemotherapy and radiation therapy.
   
• Further, the growing prevalence of cancer globally supports the rapid expansion of this segment. For instance, in 2025, approximately 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the U.S. alone.
   
• The neurological disorders segment held the second-largest market share in 2024, with a revenue of USD 2.3 billion.
   
• The increasing prevalence of neurological conditions, combined with successful clinical trials and approvals of therapies targeting these diseases, is driving significant investment and development in this segment.
   
• As research continues to deliver new gene-based treatments, the neurological disorders segment is anticipated to witness continuous growth over the forecast period.

Learn more about the key segments shaping this market

Download Free PDF

Based on the end use, gene therapy market is classified into hospitals, specialty clinics and gene therapy centers, academic and research institutions, and other end users. The hospital segment dominated the market in 2025 with a market share of 56.3%.   
 

• The hospitals segment commands a significant share of the market, serving as the primary setting for the administration and delivery of these advanced treatments.
   
• Hospitals offer specialized infrastructure, skilled healthcare professionals, and the supportive care required to manage the complex procedures and monitoring associated with gene therapies.
   
• Many hospitals are increasingly collaborating with biotech firms and participating in clinical trials, further strengthening their position in the gene therapy ecosystem.

North America Gene Therapy Market

The North America market dominated the global market with a market share of 50.7% in 2025.
 

• A favorable regulatory environment, strong financial and investment support, advanced healthcare infrastructure, and robust research and development ecosystem are key factors driving regional market growth.
   
• North America, particularly the U.S., has a well-established research and development ecosystem in the field of gene therapy. It is home to leading academic institutions, research centers, and biotechnology companies that actively contribute to advancements in gene therapy research. This ecosystem fosters innovation, attracts investment, and drives the development of novel gene therapies.
   
• Furthermore, the high prevalence of genetic disorders and complex diseases, such as cancer, in North America has created substantial demand for innovative treatment options like gene therapy.
   
• Additionally, the willingness of payers to support these therapies through reimbursement programs further fuels market growth.
   

The U.S. gene therapy market size reached USD 4.7 billion in 2025, growing from USD 4.2 billion in 2024.
 

• The U.S. continues to dominate the market, driven by its robust biotechnology ecosystem, substantial research funding, and a favorable regulatory environment.
   
• The country hosts several leading pharmaceutical and biotechnology companies and benefits from a strong pipeline of innovative gene therapy candidates and cutting-edge technologies.
   
• Additionally, the presence of top-tier research institutions and extensive clinical trial activities further accelerates the development and commercialization of new therapies.
   

Europe Gene Therapy Market

Europe market accounted for USD 2.67 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe holds a significant share of the global market, supported by its advanced healthcare infrastructure, increasing government initiatives, and rising investments in biotechnology development.
   
• The region benefits from a highly collaborative ecosystem involving academic institutions, research organizations, and pharmaceutical companies, which accelerates the development and adoption of gene therapies.
   

Germany dominates the Europe gene therapy market, showcasing strong growth potential.
 

• Within Europe, Germany holds a substantial share of the market, supported by its advanced medical research infrastructure, strong industrial base, and favorable government initiatives.
   
• The country’s emphasis on precision medicine and biotechnology has created a dynamic environment for the development and commercialization of gene therapies.
   
• Moreover, Germany’s robust healthcare system and high patient access rates further facilitate the adoption of these innovative treatments.
   

Asia Pacific Gene Therapy Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 23.2% during the analysis timeframe.
 

• The Asia Pacific region is experiencing rapid growth in the global market, driven by increasing healthcare investments, a rising incidence of genetic disorders, and greater access to advanced medical technologies.
   
• Governments across the region are strengthening biotech infrastructure and supporting clinical research through funding initiatives and international collaborations.
   
• Furthermore, the region’s large patient population, growing awareness of genetic diseases, and expanding presence of local biotechnology companies are fueling demand for innovative gene therapy solutions.
   

China gene therapy market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China dominates the Asia Pacific market, driven by substantial biotech R&D investment, supportive government policies, and a rapidly expanding clinical trial landscape.
   
• The Chinese government has prioritized genomics and advanced therapies within its national health and innovation agenda, providing significant funding and implementing regulatory reforms to foster growth.
   
• With strong manufacturing capabilities, expanding healthcare infrastructure, and rising domestic demand, China is at the forefront of gene therapy innovation in the Asia Pacific region.
   

Latin American Gene Therapy Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil is emerging as a key growth center in the Latin America market, driven by an expanding healthcare sector, increasing investment in biotechnology, and a rising prevalence of genetic disorders.
   
• The country’s large population and improving access to advanced medical treatments are generating strong demand for innovative therapies.
   
• Additionally, supportive regulatory reforms and the establishment of public-private partnerships are encouraging clinical research and local development of gene therapies.
   

Middle East and Africa Gene Therapy Market

South Africa market to experience substantial growth in the Middle East and Africa market in 2024.
 

• South Africa is demonstrating significant growth potential in the Middle East and Africa market, driven by rapidly developing medical infrastructure and a rising focus on genetic research.
   
• The country is home to several prominent research institutions and shows growing interest in addressing inherited and chronic diseases through innovative treatments.
   
• Increased collaboration with global biotechnology firms, along with government initiatives to strengthen healthcare delivery, is expected to further drive market growth.
   

Gene Therapy Market Share

The competitive landscape of the market is characterized by intense innovation and collaboration among established pharmaceutical giants, emerging biotech startups, and academic institutions. Top players such as Novartis, bluebird bio, Spark Therapeutics, Vertex Pharmaceuticals, and Pfizer hold a combined market share of ~37% in the global market. These players are continuously investing in research and development to expand their pipelines and enhance delivery technologies. The market also sees strategic partnerships, mergers, and acquisitions aimed at accelerating the commercialization of novel therapies and accessing new markets.
 

Additionally, smaller players and niche biotech firms contribute by focusing on specialized therapies and cutting-edge technologies like CRISPR and non-viral vectors. This dynamic environment fosters rapid technological advancements and competitive differentiation, driving the overall growth and diversification of the market.
 

Gene Therapy Market Companies

Prominent players operating in the market are as mentioned below:

• Amgen
• Applied Genetic Technologies Corporation (AGTC)
• Audentes Therapeutics, Inc. (Astellas Pharma)
• Bayer
• Beam Therapeutics
• BioMarin Pharmaceutical
• bluebird bio
• Bristol-Myers Squibb Company
• CRISPR Therapeutics
• Gilead Sciences
• Helixmith
• Intellia Therapeutics
• Krystal Biotech
• Novartis
• Orchard Therapeutics
• Pfizer
• Sangamo Therapeutics
• Sarepta Therapeutics
• Spark Therapeutics (Roche)
• UniQure N.V.
   
• Novartis

Novartis is a key player in the market with a leading market share of ~15.2. The company is primarily known for its groundbreaking treatment Zolgensma, used to combat spinal muscular atrophy (SMA). The company’s strong focus on rare genetic disorders and its robust manufacturing capabilities have positioned it at the forefront of gene therapy innovation and commercialization.
 

• Spark Therapeutics (Roche)

Acquired by Roche, Spark Therapeutics is a pioneer in gene therapy, best known for Luxturna, the first FDA-approved gene therapy for inherited retinal diseases. The company combines cutting-edge research with Roche’s global reach, accelerating the development and accessibility of novel gene-based treatments.
 

• Vertex Pharmaceuticals
  Vertex Pharmaceuticals is a key player in the market, focusing on innovative treatments for genetic blood disorders such as sickle cell disease and beta-thalassemia. Their work with CRISPR-based gene editing technology exemplifies their commitment to precision medicine. With a strong pipeline and strategic partnerships, Vertex is advancing cutting-edge therapies that have the potential to transform patient outcomes into inherited diseases.

Gene Therapy Industry News

• In June 2026, Merck KGaA announced that it would acquire Bio-Techne for USD 11.3 billion (USD 73 per share), representing a 24% premium over Bio-Techne's previous closing price. The acquisition expands Merck's capabilities in cell and gene therapy, life science research, and precision diagnostics, with the company expecting €140 million in annual cost synergies within three years after closing.
• In October 2025, AstraZeneca announced that it had signed a licensing agreement worth up to USD 555 million with Algen Biotechnologies to develop AI-enabled gene therapies for immune system-related disorders. Under the agreement, AstraZeneca obtained exclusive global development and commercialization rights, while Algen is eligible for upfront and milestone payments totaling up to USD 555 million.
• In August 2025, Kite Pharma, a Gilead Sciences company, announced that it had entered into a definitive agreement to acquire Interius BioTherapeutics for USD 350 million in cash. The acquisition strengthens Kite Pharma's in vivo CAR T-cell therapy platform by adding Interius' intravenous gene delivery technology, which is designed to simplify CAR T-cell manufacturing. The transaction is expected to reduce Gilead's 2025 earnings per share by approximately USD 0.23–0.25 and remains subject to customary regulatory approvals.

The gene therapy market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vector

• Viral vectors 
  • Retro viral vectors
  • Adeno-associated virus vectors
  • Lentiviral vectors
  • Other viral vectors
• Non-viral vectors     
  • Plasmid DNA
  • Lipid nanoparticles (LNPs)
  • Oligonucleotides
  • Other non-viral vectors

Market, By Delivery Method

• In vivo gene therapy
• Ex vivo gene therapy

Market, By Gene Type

• Antigen-encoding genes
• Cytokine-encoding genes
• Tumor suppressor genes
• Suicide genes
• Gene replacement (for deficiency)
• Growth factor genes
• Receptor-encoding genes
• Other gene types

Market, By Indication

• Oncology      
  • Acute lymphoblastic leukemia (ALL)
  • Large B-cell lymphoma
  • Head & neck squamous cell carcinoma
  • Melanoma
• Neurological disorders        
  • Duchenne muscular dystrophy (DMD)
  • Spinal muscular atrophy (SMA)
• Hemophilia A & B    
• Hepatological diseases       
• Inherited retinal disease     
• Peripheral arterial disease  
• Other indications     

Market, By End Use

• Hospitals
• Specialty clinics and gene therapy centers
• Academic and research institutions
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE